Prospects for the development of new vaccine adjuvants

BioDrugs

Volumn 12, Issue 6, 1999, Pages 439-453

  Cox, John ^a   Coulter, Alan ^a  

^a CSL LIMITED   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; INFLUENZA VACCINE;

ANTIBODY RESPONSE; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFLUENZA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK BENEFIT ANALYSIS; VACCINATION; VACCINE PRODUCTION;

EID: 0033400131     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199912060-00004     Document Type: Review

References (113)

1. 1. Ada GL. The traditional vaccines: an overview. In: Levine MM, Woodrow GC, Kaper JB, editors. 2nd ed. New generation vaccines. New York: Marcel Dekker, Inc. 1997; 2: 13
2. 2. Grange JM, Stanford JL. Therapeutic vaccines. J Med Microbiol 1996; 45: 81-3
3. 3. Cox JC, Coulter AR. Adjuvants-a classification and review of their modes of action. Vaccine 1997; 15 (3): 248-56
4. 4. Ada GL. The next steps. Dev Biol Stand 1994; 82: 251-6
5. 5. Oussoren C, Zuidema J, Crommelin DJA, et al. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection .II. Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta 1997; 1328 (2): 261-72
6. 6. Cox JC, Coulter AR. Advances in adjuvant technology and application. In: Yong WK, editor. Animal parasite control utilizing biotechnology. Boca Raton: CRC Press, 1992; 4: 49-112
7. 7. Coulter A, Wong TY, Drane D, et al. Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines. Vaccine 1998; 16: 1243-53
8. 8. Heppner DG, Gordon DM, Gross M, et al. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J Infect Dis 1996; 174: 361-6
9. 9. Blagowechensky NN. Duree du sejour de l'antigene dans l'organisme et immunite. Rev Immunol (Paris) 1938; 4: 161-74
10. 10. Farago F, Ujhelyi K. Neuere untersuchungen uber die depotwirkung des niederschlaghaltigen impfstoffes. Z Immunol Forsch 1942; 101: 178-83
11. 11. Bomford R. Aluminium salts: perspectives in their use as adjuvants. In: Immunological adjuvants and vaccines. Gregoriadis G, et al. editors. NATO ASI Series A: Life Sciences Vol. 179. Proceedings of a NATO Advanced Study Institute; 1988 Jun 24-Jul 5; Cape Sounion, Greece. New York: Plenum Press, 1989; 35-41
12. 12. Mancino D, Ovary Z. Adjuvant effects of amorphous silica and of aluminium hydroxide on IgE and IgG1 antibody production in different inbred mouse strains. Int Arch Allergy Appl Immunol 1980; 61: 253-8
13. 13. Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121: 947-52
14. 14. Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993; 270 (16): 1956-61
15. 15. Govaert TME, Thijs CTMCN, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994; 272 (21): 1661-5
16. 16. Nguyen-Van-Tam JS, Nicholson KG. Influenza immunization; vaccine offer, request and uptake in high-risk patients during the 1991/2 season. Epidemiol Infect 1993; 111: 347-55
17. 17. Salk JE, Bailey ML, Laurent AM. The use of adjuvants in studies on influenza immunization. II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water-in-oil emulsion. Am J Hyg 1952; 55: 439-56
18. 18. Salk JE, Contakos M, Laurent AM, et al. Use of adjuvants in studies on influenza immunization. 3. Degree of persistence of antibody in human subjects two years after vaccination. JAMA 1953; 151: 1169-75
19. 19. Beebe GW, Simon AH, Vivona S. Follow-up study on army personnel who received adjuvant influenza virus vaccine 1951-1953. Am J Med Sci 1964; 247: 385-406
20. 20. Glück R, Mischler R, Finkel B, et al. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994; 344: 160-3
21. 21. Keitel W, Couch R, Bond N, et al. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 1993; 11: 909-13
22. 22. Keefer MC, Graham BS, McElrath MJ, et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. AIDS Res Hum Retroviruses 1996; 12: 683-93
23. 23. Ott G, Barchfeld GL, Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995; 13: 1557-62
24. 24. Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 1996; 14: 478-84
25. 25. Martin TJ. Enhanced immunogenicity of Chiron Biocine adjuvanted influenza vaccine in the elderly. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III. Amsterdam: Elsevier Science B.V., 1996; 647-52
26. 26. Minutello M, Senatore F, Cecchinelli G, et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999; 17: 99-104
27. 27. Cox J, Coulter A, Macfarlan R, et al. Development of an Influenza-Iscom Vaccine. In: Gregoriadis G, editor. Vaccine design: the role of cytokine networks. NATO ASI Series A: Life Sciences Vol. 282. Proceedings of a NATO Advanced Study Institute; 1996 Jun 24-Jul 5; Cape Sounion, Greece. New York: Plenum Press, 1997; 33-49
28. 28. Data on file, CSL Ltd. Research and Development Division, 1997
29. 29. Bates J, Ackland J, Coulter A, et al. Options for the control of influenza III. In: Brown LE, Hampson AW, Webster RG, editors, Iscom adjuvant - a promising adjuvant for influenza virus vaccines. Amsterdam: Elsevier Science B.V., 1996; 661-7
30. 30. Ennis FA, Cruz J, Jameson J, et al. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanled carriers (ISCOMS). Virology 1999; 259: 256-61
31. 31. Davenport FM, Hennessy AV, Askin FB. Lack of adjuvant effect of AIPO4 on purified influenza virus hemagglutinins in man. J Immunol 1968; 100: 1139-40
32. 32. Aguado T, Engers H, Pang T, et al. Meeting Report - Novel Adjuvants Currently in Clinical Testing (sponsored by the World Health Organization). 1998 Nov 2-4; Foundation Mérieux, Annecy, France
33. 33. Payne LG, Jenkins SA, Woods AL, et al. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant tor an influenza vaccine. Vaccine 1998; 16: 92-8
34. 34. Palache AM, Beyer WEP, Hendriksen E, et al. Adjuvancy and reactogenicity of N-acetylglucosaminyl N-acetylmuramyl dipeptide (GMDP) orally administered just prior to trivalent influenza subunit vaccine. A double-blind placebo-controlled study in nursing home residents. Vaccine 1996; 14: 1327-30
35. 35. Kriesel JD, Spruance J. Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. Vaccine 1999; 17: 1883-8
36. 36. Daynes RA, Araneo BA. The development of effective vaccine adjuvants employing natural regulators of T-cell lymphokine production in vivo. Ann N Y Acad Sci 1994; 730: 144-61
37. 37. Wyerth-Ayerst returns vaccine adjuvant rights. Press release from the Liposome Co. PR Newswire 1995 Mar 14
38. 38. Powers DC, Manning MC, Hanscome PJ, et al. Lymphocyte responses to a liposome-adjuvanted influenza A virus vaccine in the elderly. J Infect Dis 1995; 172: 1103-7
39. 39. Evans TG, McElrath MJ, Gorse G, et al. Dose sparing adjuvant effect of QS21 in combination with a recombinant MN gp120 in immunization of HIV-1 uninfected volunteers (AVEG 016G). Clin Infect Dis 1997; 25 (2): 393
40. 40. Thoelen S, Van Damme P, Mathei C, et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998; 16: 708-14
41. 41. SmithKline Beecham and Ribi announce positive hepatitis B phase III trial data. Press release, 1998 Dec 14. Chemical Business Newsbase, Roy Soc Chem 1998
42. 42. Carlsson T, Struve J. Granulocyte-macrophage colony-stimulating factor given as an adjuvant to persons not responding to hepatitis B vaccine. Infection 1997; 25: 129
43. 43. Decker K. Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J Biochem 1990; 192: 245-61
44. 44. Aquila announces initial results of phase II clinical trial of Quilimmune-P to prevent pneumococcal infections. Press release from Aquila Biopharmaceuticals Inc., 1998 Oct 14. Chemical Business Newsbase, Roy Soc Chem 1998
45. 45. Fattal-German M, Taillandier J, Mathieu D, et al. Pneumococcal vaccination of elderly individuals. Vaccine 1991; 9: 542-4
46. 46. Glück R, Mischler R, Brantschen S, et al. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 1992; 90: 2491-5
47. 47. Poland GA. The role of sodium bisulfite in the 1996-1997 USA influenza vaccine recall. Vaccine 1998; 16: 1865-8
48. 48. Sigal LH, Zahradnik JM, Lavin P, et al. A vaccine consisting of recombinant borrelia burgdorferi outer surface protein A to prevent lyme disease. N Engl J Med 1998; 339 (4): 216-22
49. 49. Lawrence GW, Saul A, Giddy AJ, et al. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 1997; 15: 176-8
50. 50. Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997; 336: 86-91
51. 51. Hoon DS, Irie RF. Current status of human melanoma vaccines. Can they control malignant melanoma? BioDrugs 1997; 7 (1): 66-84
52. 52. Thurin J, Thurin M, Herlyn M, et al. GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. FEBS Lett 1986; 208 (1): 17-22
53. 53. Livingston PO, Natoli EJ, Calves MJ, et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci U S A 1987; 84: 2911-5
54. 54. Livingston PO, Wong GY, Adluri S, et al. A randomized trial of adjuvant vaccination with BCG versus BCG plus the melanoma ganglioside GM2 in AJCC stage 111 melanoma patients. J Clin Oncol 1994; 12: 1036-44
55. 55. Helling F, Shang A, Calves MJ, et al. GD3 vaccines for melanoma: superior immunogenicity of KLH conjugate vaccines. Cancer Res 1994; 54: 197-203
56. M2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995; 55: 2783-8
57. 57. Livingston P, Zhang S, Adluri S, et al. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Cancer Immunol Immunother 1997; 43: 324-30
58. 58. Dickler MN, Grant SC, Ragupathi G, et al. Vaccination with Fucosyl-GMI (FUC-GMI) - keyhold limpet hemocyanin (KLH) conjugate plus QS-21 in patients with small cell lung cancer (SCLC) after a major response to therapy. Abstract Proceedings of ASCO 1998; 17: 434a
59. 59. Cox JC, Ronnberg B, Sjolander S, inventors. Ganglioside immunostimulating complexes and uses thereof. Australia. 1999; PCT/AU98/00453
60. 60. Mitchell MS, Harel W, Kan-Mitchell J, et al. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann N Y Acad Sci 1993; 690: 153-66
61. 61. MacLean GD, Miles DW, Rubens RD, et al. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunol 1996; 19 (4): 309-16
62. 62. Biomira begins pivotal phase 3 trial of theratope(R) cancer vaccine. Press release from Biomira, Inc., PR Newswire 1998 Nov 30
63. 63. Gilewski T, Adluri R, Zhang S, et al. MUC-1 keyhole limpet hemocyanin (KLH) conjugate plus QS-21 vaccination of high risk breast cancer patients (BCPts) with no evidence of disease (NED). Proceedings of ASCO 1997; 16: 438a
64. 64. Apostolopoulos V, Pietersz GA, Loveland BE, et al. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci U S A 1995; 92: 10128-32
65. 65. Karanikas V, Hwang LA, Pearson J, et al. Antibody and T-cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997; 100 (11): 2783-92
66. 66. Apostolopoulos V, Osinski C, McKenzie IF. MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat Med 1998; 4 (3): 315-20
67. 67. McCaffery M, Yao T, Williams L, et al. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Can Res 1996; 2: 679-86
68. 68. Triozzi PL, Gochnour D, Martin EW, et al. Clinical and immunologic effects of a synthetic Beta-human chorionic gonadotropin vaccine. Int J Oncol 1994; 5: 1447-53
69. 69. Todd CW, Pozzi LAM, Guarnaccia JR, et al. Development of an adjuvant active nonionic block copolymer for use in oil-free subunit vaccines formulations. Vaccine 1997; 15: 564-70
70. 70. Triozzi PL, Stevens VC, Aldrich W, et al. Phase I Trial of a novel nonionic block copalymer adjuvant, CRL 1005, with a synthetic beta-human chorionic gonadotropin subunit immunogen administered in aqueous solution. Clin Can Res 1997; 12: 2355-66
71. 71. Berd D, Maguire HCJ, Schuchter LM, et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997; 15 (6): 2359-70
72. 72. Berd D, Maguire HCJ, McCue P, et al. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990; 8 (11): 1858-67
73. 73. Eton O, Kharkevitch DD, Gianan MA, et al. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. Clin Can Res 1998; 4: 619-27
74. 74. Ollila DW, Kelley MC, Gammon G, et al. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. Semin Surg Oncol 1998; 14: 328-36
75. 75. Barth A, Hoon DS, Foshag LJ, et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in-vitro cellular immune response. Cancer Res 1994; 54: 3342-5
76. 76. Mitchell MS, Kan-Mitchell J, Kempf RA, et al. Active specfic immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988; 48: 5883-93
77. 77. Mitchell MS, Von Eschen KB. Phase III trial of melacine melanoma theraccine vs. combination chemotherapy in the treatment of stage IV melanoma [abstract]. Proc Am Soc Clin Oncol 1997; 16: 1788
78. 78. Schultz N, Oratz R, Chen D, et al. Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine 1995; 13: 503-8
79. 79. Marsh BJ, von Reyn CF, Arbeit RD, et al. Immunisation of HIV - infected adults with a three-dose series of inactivated Mycobacterium vaccae. Am J Med Sci 1997; 313: 377-83
80. 80. Hrouda D, Souberbielle BE, Kayaga J, et al. Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer. Br J Urol 1998; 82 (6): 870-6
81. 81. Bottasso O, Merlin V, Cannon L, et al. Studies of vaccination of persons in close contact with leprosy patients in Argentina. Vaccine 1998; 16 (11-12): 1166-71
82. 82. Thompson HSG, Davies ML, Holding FP, et al. Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine 1999; 17: 40-9
83. 83. HPV vaccine shows efficacy for genital warts at six months. Antiviral Agents Bull 1997; 10 (12): 364
84. 84. Morein B, Lövgren-Bengtsson K, Cox J. Modern adjuvants. Functional aspects. In: Kaufmann SHE, editor. Concepts in vaccine development. Berlin: Walter de Gruyter, 1996; 3: 243-63
85. 85. Van Binnendijk RS, Poelen MC, van Amerongen G, et al. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles in the presence of passively acquired antibodies. J Infect Dis 1997; 175: 524-32
86. 86. Eldridge JH, Hammond CJ, Meulbroek JA, et al. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release 1990; 11: 205-14
87. 87. Moldoveanu Z, Novak M, Huang W-Q, et al. Oral immunization with influenza virus in biodegradable microspheres. J Infect Dis 1993; 167: 84-90
88. 88. Hirst TR, Nashar TO, Pitman RS, et al. Cholera toxin and related enterotoxins as potent immune modulators. J Appl Microbiol 1998; 84 Suppl. 26S-34S
89. 89. Scott, D. Evaluation of E. coli heat labile toxin (LT) as an oral mucosal adjuvant for enteric vaccines [abstract]. Presented at IBC Conference - Mucosal Immunisation, Genetic approaches and Adjuvants; 1995 Oct 16-18; Rockville, MD USA
90. 90. DeNoon DJ. Conference coverage (ICAAC) travellers' diarrhea vaccine safe, immunogenic. Vaccine Wkly 1997 Oct 27; 4
91. 91. Kreiss C, Porta N, Kotloff K, et al. Oral immunization with recombinant urease and LT adjuvant in Helicobacter pyloriinfected humans. I J M S 1997; 166 Suppl. 3: 8-9
92. 92. Rappuoli R, Mariagrazia P, Kaufmann SHE, editors. Concepts in vaccine development. Genetic detoxification of bacterial toxins. Berlin: Walter de Gruyter & Co., 1996; 3.5: 361-77
93. 93. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immunol 1995; 63: 1617-23
94. 94. Sjolander S, Drane D, Davis R, et al. Intranasal Immunisation with A/PR8-Iscom induces cytotoxic T-cell responses and protection against infection. Abstract Presented at the 3rd Australian Peptide Conference: From Discovery to Therapeutics; 1998 Oct 4-9; Whitsundays, Queensland. Vaccine Wkly 1998 Dec 28; 12
95. 95. McCluskie MJ, Davis HL. Cutting edge: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998; 161: 4463-6
96. 96. Horner AA, Ronaghy A, Cheng P, et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol 1998; 190: 77-82
97. 97. Schwartz DA, Quinn TJ, Thorne PS, et al. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J Clin Invest 1997; 100 (1): 68-73
98. 98. Yang NS, Burkholder J, Roberts B, et al. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci U S A 1990; 87 (24): 9568-72
99. 99. Cox JC, Sparks RE, Jacobs IC, et al., inventors. Vaccine preparations. 1994; PCT/AU93/00677
100. 100. Glenn GM, Rao M, Matyas GR, et al. Skin immunization made possible by cholera toxin. Nature 1998; 391: 851
101. 101. Araneo BA, Woods ML, Daynes RA. Reversal of the immunoserescent phenotype by dehydroepiandrosterone: hormone treatment provides an adjuvant effect on the immunisation of aged mice with recombinant Hepatitis B surface antigen. J Infect Dis 1993; 167: 830-40
102. 102. Degelau J, Guay D, Hallgren H. The effect of DHEAS on influenza vaccination in aging adults. J Am Geriatr Soc 1997; 45: 747-51
103. 103. Araneo B, Dowell T, Woods ML, et al. DHEAS as an effective vaccine adjuvant in elderly humans - Proof-of-principle studies. Ann N Y Acad Sci 1995; 774: 232-48
104. 104. Rook GAW, Stanford JL. Adjuvants, endocrines and conserved epitopes; factors to consider when designing "therapeutic vaccines". Int J Immunopharmacol 1995; 17: 91-102
105. 105. Eldridge JH, Staas JK, Meulbroek JA, et al. Biodegradable microspheres as a vaccine delivery system. Mol Immunol 1991; 28: 287-94
106. 106. Kersten GFA, Gander B. Biodegradable microspheres as vehicles for antigens. In: Kaufman SHE, editor. Concepts in vaccine development. Berlin: Walter de Gruyter, 1996; 3.2: 265-302
107. 107. Cleland JL, Mac A, Boyd B, et al. The stability of recombinant human growth hormone in poly (lactic-co-glycolic acid) (PLGA) microspheres. Pharmacol Res 1997; 14 (4): 420-5
108. 108. Marciani DJ, Kensil CR, Beltz GA, et al. Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. Vaccine 1991; 9: 89-96
109. 109. Byars NE, Nakano G, Welch M, et al. Use of Syntex adjuvant formulation to augment humoral responses to Hepatitis B virus surface antigen and to influenza virus hemagglutinin. In: Gregoriadis G, Allison AC, Poste G, editors. Immunolgical adjuvants and vaccines, NATO ASI Series A: Life Sciences Vol. 1979. Proceedings of a NATO Advanced Study Inst. Immunological Adjuvants and Vaccines; 1988 Jun 24-Jul 5; Cape Sounion Beach, Greece. New York: Plenum Press, 1989; 145
110. 110. Cox JC. Adjuvants. Australas Biotechnol 1998; 8 (3): 148-52
111. 111. Brodie SJ, Lewinsohn DA, Patterson BK, et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med 1999; 5 (1): 34-41
112. + CTLs are essential for protective immunity against Encephalitozoon cuniculi infection. J Immunol 1999; 162: 6086-91
113. 113. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18 (2): 89-95